MEDVi Examined: Is It Legit? Benefits, Safety, Complaints, and Customer Feedback

A physician-monitored telehealth platform for GLP-1 weight loss therapy

Published on Feb. 8, 2026

Got story updates? Submit your updates here. ›

MEDVi is a telehealth service that connects patients with licensed clinicians to receive physician-supervised GLP-1 weight loss treatment. The platform provides access to compounded GLP-1 medications through licensed U.S. pharmacies, focusing on medical responsibility, regulatory transparency, and patient involvement.

Why it matters

Telehealth services like MEDVi aim to increase access to medically-supervised weight loss treatments, which can be particularly beneficial for those with limited access to in-person specialists or who prefer a discreet care option. However, the use of compounded medications raises regulatory and ethical concerns that need to be addressed.

The details

MEDVi's model involves an initial health assessment, virtual consultation with a licensed clinician, and potential prescription of compounded GLP-1 medications like semaglutide or tirzepatide. The clinicians make all treatment decisions and maintain ongoing communication with patients to monitor for side effects and adjust dosages as needed. While compounded GLP-1 drugs are not FDA-approved, MEDVi emphasizes transparency about their regulatory status.

  • MEDVi was launched in 2026.

The players

MEDVi

A telehealth service that facilitates access to physician-supervised GLP-1 weight loss therapy.

Licensed clinicians

Medical professionals who evaluate patients, determine appropriate treatment, and provide ongoing supervision through MEDVi's platform.

U.S. licensed compounding pharmacies

Pharmacies that manufacture the compounded GLP-1 medications prescribed through MEDVi.

Got photos? Submit your photos here. ›

What’s next

MEDVi plans to continue expanding its network of licensed clinicians and compounding pharmacies to improve access to its physician-supervised GLP-1 weight loss therapy across the United States.

The takeaway

MEDVi's telehealth model for GLP-1 weight loss treatment aims to balance the convenience of remote care with the oversight and safety of licensed medical professionals. However, the use of compounded medications raises regulatory concerns that the company will need to navigate carefully to build trust and credibility with patients.